740 Y-P TFA 3956 used as a conjugated drug

used as a conjugated drug of HER2-targeting ADC (DS-8201a)

SP600125 (20 μM) blocks the G2 phase to mitosis transition and induces endoreplication

Administration of sitagliptin in vivo reduces lymph node and splenic CD4+ T-cell migration

KW-2449 increases the percentage of cells in the G1 phase of the cell cycle and reciprocally reduces the percentage of cells in the S phase

Desoximetasone activates specific intracellular receptors

740 Y-P TFA 3956 used as a conjugated drug740 Y P TFA is a potent and cell permeable PI3K activator. 740 Y P TFA readily binds GST fusion proteins containing both the N and C terminal SH2 domains of p85 but fails to bind GST alone. Product information Molecular Weight: 3384. 73 Formula: C143H223F3N43O41PS3 Chemical Name: (3S) 3 [[(2S) 2 [[(2S) 2 [[2 [[2 [[(2S) 2 [[(2S) 2 [[(2S) 6 amino 2 [[(2S) 6 amino 2 [[(2S) 2 [[(2S) 6 amino 2 [[(2S) 2 [[(2S) 2 [[(2S) 2 [[(2S) 4 amino 2 [[(2S) 5 amino 2